CTI BioPharma (CTIC) 10-Q2021 Q3 Quarterly report

Filed: 12 Nov 21, 5:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: anniversary, annum, automatically, burden, calendar, consecutive, contemplated, count, customary, DRI, earliest, ease, expedient, extinguishment, extraordinary, indemnification, instrument, Interbank, irrevocably, leaseback, LIBOR, London, LP, mandatory, monetization, prepay, prepayment, referenced, released, repaid, tiered, topline, trailing, twelve, unfunded, unrestricted

Removed: accurately, acquire, activation, adequately, adult, advanced, advancement, ameliorate, approximate, assigned, Baxalta, begin, certainty, collaborative, commercializing, consent, contractual, cycle, daily, demonstrate, dependent, detail, developed, discharge, discretion, efficacy, eligible, enhance, enrolled, estimate, evidence, execute, expedited, experience, exposed, extent, face, found, function, hospital, human, initial, interpreted, intolerable, longer, lower, macrophage, mg, mitigate, monitor, month, multiple, outpatient, pace, partner, pathological, perform, personal, preclude, predict, project, proximity, reach, reacquisition, reaction, regulate, respiratory, responsibility, resumed, schedule, sharing, signaling, size, sought, specifically, stage, storm, suffered, SVB, treated, unacceptable, upregulated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CTIC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Adam R. Craig, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of CTI BioPharma Corp., that, to my knowledge, the Quarterly Report of CTI BioPharma Corp. on Form 10-Q for the fiscal quarter ended September 30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.

A signed original of this written statement required by Section 906 has been provided to CTI BioPharma Corp. and will be retained by CTI BioPharma Corp. and furnished to the Securities and Exchange Commission or its staff upon request.


Dated: November 12, 2021	By:	/s/ Adam R. Craig
		Adam R. Craig
		President, Chief Executive Officer and Interim Chief Medical Officer

I, David H. Kirske, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of CTI BioPharma Corp., that, to my knowledge, the Quarterly Report of CTI BioPharma Corp. on Form 10-Q for the fiscal quarter ended September 30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents in all material respects the financial condition and results of operations of CTI BioPharma Corp.


Dated: November 12, 2021	By:	/s/ David H. Kirske
		David H. Kirske
		Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.